Dana Investment Advisors, Inc. Supernus Pharmaceuticals, Inc. Transaction History

Dana Investment Advisors, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$42.7 - $56.55 $2 Million - $2.64 Million	-46,749 Closed	0 $0
Q2 2018 Aug 01, 2018	SELL	$44.1 - $59.85 $434,693 - $589,941	-9,857 Reduced 17.41%	46,749 $0
Q1 2018 May 15, 2018	SELL	$37.15 - $46.9 $29,645 - $37,426	-798 Reduced 1.39%	56,606 $2.59 Million
Q4 2017 Feb 13, 2018	SELL	$36.4 - $42.6 $24,096 - $28,201	-662 Reduced 1.14%	57,404 $0
Q3 2017 Nov 15, 2017	BUY	$36.75 - $49.65 $2.13 Million - $2.88 Million	58,066	58,066 $2.32 Million

303

60.6M

22.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.79B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Dana Investment Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Dana Investment Advisors, Inc. with notifications on news.